DMT — Small Pharma Share Price
Last trade - 00:00- CA$48.67m
- CA$41.47m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.12 | ||
| Price to Tang. Book | 1.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -141.69% | ||
| Return on Equity | -78.43% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 28th Feb | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | 0.16 | 0.08 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Small Pharma Inc. is a Canada-based neuroscience company that is focused on discovering and developing novel treatments for mental health conditions, with a focus on depression. The Company makes medicines based on known active ingredients and specializes in IP-led development of treatments for mental health conditions through the development of psychedelic and non-psychedelic medicines. The Company’s dimethyltryptamine (DMT) assisted therapy candidates include SPL028 and SPL026. The Company initiated a clinical program into DMT-assisted therapy, including a Phase I/IIa trial on the Company’s lead candidate alongside development of a robust pipeline of proprietary preclinical assets. The Company seeks to initiate Phase I study of SPL028 with psychotherapy among healthy volunteers to assess safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration. SPL026 is a clinical development program with psychotherapy.
Directors
- Last Annual
- February 28th, 2023
- Last Interim
- February 28th, 2023
- Incorporated
- January 23rd, 2018
- Public Since
- November 16th, 2018
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 321,562,487
- Address
- 6-8 Bonhill Street; 3rd Floor, Vancouver, EC2A 4BX
- Web
- Phone
- +1 6046892646
- Auditors
- MNP LLP
Upcoming Events for DMT
Similar to DMT
Arch Biopartners
TSX Venture Exchange
biOasis Technologies
TSX Venture Exchange
Ceapro
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
FAQ
As of Today at 01:21 UTC, shares in Small Pharma are trading at CA$0.06. This share price information is delayed by 15 minutes.
Shares in Small Pharma last closed at CA$0.06 and the price had moved by -40.91% over the past 365 days. In terms of relative price strength the Small Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -45.45% over the past year.
The overall consensus recommendation for Small Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Small Pharma does not currently pay a dividend.
Small Pharma does not currently pay a dividend.
Small Pharma does not currently pay a dividend.
To buy shares in Small Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.06, shares in Small Pharma had a market capitalisation of CA$22.51m.
Here are the trading details for Small Pharma:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: DMT
Based on an overall assessment of its quality, value and momentum Small Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Small Pharma is CA$3.21. That is 5257.14% above the last closing price of CA$0.06.
Analysts covering Small Pharma currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.05 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Small Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -47.59%.
As of the last closing price of CA$0.06, shares in Small Pharma were trading -37.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Small Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Small Pharma's directors